| Carbonic anhydrase inhibitors as emerging agents for the treatment and imaging of hypoxic tumors |
54 |
| Targeting inflammation in diabetic nephropathy: a tale of hope |
33 |
| Gepants for the treatment of migraine |
20 |
| Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer |
17 |
| Investigational CD33-targeted therapeutics for acute myeloid leukemia |
17 |
| C-MET inhibitors for advanced non-small cell lung cancer |
17 |
| New concepts in opioid analgesia |
17 |
| The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update |
15 |
| Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials |
15 |
| Investigational drugs in development to prevent neuromyelitis optica relapses |
14 |
| MEK inhibitors under development for treatment of non-small-cell lung cancer |
13 |
| Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy |
12 |
| Atezolizumab for the treatment of triple-negative breast cancer |
12 |
| Prostaglandin D-2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives |
12 |
| Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease |
12 |
| Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL) |
12 |
| Prospects for the introduction of targeted antioxidant drugs for the prevention and treatment of diseases related to free radical pathology |
11 |
| Targeting the B cell receptor pathway in non-Hodgkin lymphoma |
11 |
| Cefiderocol: a novel siderophore cephalosporin |
11 |
| Tau immunotherapies for Alzheimer's disease |
11 |
| Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease |
11 |
| Strategic development of AZD a Wee1 kinase inhibitor, for cancer therapy |
10 |
| Investigational BACE inhibitors for the treatment of Alzheimer's disease |
10 |
| The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review |
9 |
| Investigational drugs for hyperuricemia, an update on recent developments |
9 |
| Investigational drugs for the treatment of osteoarthritis, an update on recent developments |
9 |
| Targeting AKT for cancer therapy |
9 |
| MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis |
9 |
| An overview of hypocretin based therapy in narcolepsy |
9 |
| Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach |
8 |
| The Jakinibs in systemic lupus erythematosus: progress and prospects |
8 |
| Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC) |
8 |
| Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials |
7 |
| Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD |
7 |
| Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease |
7 |
| Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy |
7 |
| HER2-targeted therapy: an emerging strategy in advanced colorectal cancer |
7 |
| Investigational small molecules in phase II clinical trials for the treatment of epilepsy |
7 |
| Siponimod in the treatment of multiple sclerosis |
7 |
| Clinical drug development for dementia with Lewy bodies: past and present |
7 |
| Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer |
7 |
| BIIB093 (IV glibenclamide): an investigational compound for the prevention and treatment of severe cerebral edema |
7 |
| Small-molecule inhibitors and the salivary gland epithelium in Sjogren's syndrome |
6 |
| Investigational drugs for the treatment of endometriosis, an update on recent developments |
6 |
| Vilaprisan for treating uterine fibroids |
6 |
| Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis |
6 |
| Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update |
6 |
| Fevipiprant in the treatment of asthma |
6 |
| Investigational drugs for vasospasm after subarachnoid hemorrhage |
6 |
| Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints |
6 |
